Gut microbiota and metabolite interface-mediated hepatic inflammation-Immunometabolism-CSCIED科技核心评价数据库-手机版

Gut microbiota and metabolite interface-mediated hepatic inflammation

Gut microbiota and metabolite interface-mediated hepatic inflammation

ES评分 0 浏览量：1148 下载量：0

DOI	10.1097/IN9.0000000000000037
刊名	Immunometabolism IJ
年，卷(期)	2024, 6(1)
作者	Yang, Ming; Massad, Katina; Kimchi, Eric T.; Staveley-O'Carroll, Kevin F.; Li, Guangfu,
作者单位	[Yang, Ming; Massad, Katina; Kimchi, Eric T.; Staveley-O'Carroll, Kevin F.; Li, Guangfu] Univ Missouri, Dept Surg, Columbia, MO 65201 USA; [Yang, Ming; Li, Guangfu] Univ Missouri, NextGen Prec
摘要	Immunologic and metabolic signals regulated by gut microbiota and relevant metabolites mediate bidirectional interaction between the gut and liver. Gut microbiota dysbiosis, due to diet, lifestyle, bile acids, and genetic and environmental factors, can advance the progression of chronic liver disease. Commensal gut bacteria have both pro- and anti-inflammatory effects depending on their species and relative abundance in the intestine. Components and metabolites derived from gut microbiota-diet interaction can regulate hepatic innate and adaptive immune cells, as well as liver parenchymal cells, significantly impacting liver inflammation. In this mini review, recent findings of specific bacterial species and metabolites with functions in regulating liver inflammation are first reviewed. In addition, socioeconomic and environmental factors, hormones, and genetics that shape the profile of gut microbiota and microbial metabolites and components with the function of priming or dampening liver inflammation are discussed. Finally, current clinical trials evaluating the factors that manipulate gut microbiota to treat liver inflammation and chronic liver disease are reviewed. Overall, the discussion of microbial and metabolic mediators contributing to liver inflammation will help direct our future studies on liver disease.
Abstract	Immunologic and metabolic signals regulated by gut microbiota and relevant metabolites mediate bidirectional interaction between the gut and liver. Gut microbiota dysbiosis, due to diet, lifestyle, bile acids, and genetic and environmental factors, can advance the progression of chronic liver disease. Commensal gut bacteria have both pro- and anti-inflammatory effects depending on their species and relative abundance in the intestine. Components and metabolites derived from gut microbiota-diet interaction can regulate hepatic innate and adaptive immune cells, as well as liver parenchymal cells, significantly impacting liver inflammation. In this mini review, recent findings of specific bacterial species and metabolites with functions in regulating liver inflammation are first reviewed. In addition, socioeconomic and environmental factors, hormones, and genetics that shape the profile of gut microbiota and microbial metabolites and components with the function of priming or dampening liver inflammation are discussed. Finally, current clinical trials evaluating the factors that manipulate gut microbiota to treat liver inflammation and chronic liver disease are reviewed. Overall, the discussion of microbial and metabolic mediators contributing to liver inflammation will help direct our future studies on liver disease.
关键词	liver inflammation; gut microbiota; metabolite; metabolic regulation; chronic liver disease; clinical trials
KeyWord	liver inflammation; gut microbiota; metabolite; metabolic regulation; chronic liver disease; clinical trials
基金项目
页码	1-12

参考文献
相关文献

[1]. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55-64.

[2]. Zhang CY, Liu S, Yang M. Antioxidant and anti-inflammatory agents in chronic liver diseases: molecular mechanisms and therapy. World J Hepatol. 2023;15(2):180-200.

[3]. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.

[4]. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-9.

[5]. Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349-64.

[6]. Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558-77.

[7]. Wei B, Peng Z, Xiao M, et al. Modulation of the microbiome-fat-liver axis by lactic acid bacteria: a potential alleviated role in high-fat-diet-induced obese mice. J Agric Food Chem. 2023;71(27):10361-74.

[8]. Wu YY, Gou W, Yan Y, et al. Gut microbiota and acylcarnitine metabolites connect the beneficial association between equol and adiposity in adults: a prospective cohort study. Am J Clin Nutr. 2022;116(6):1831-41.

[9]. Eliuz Tipici B, Coskunpinar E, Altunkanat D, et al. Lactobacillus GG is associated with mucin genes expressions in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Eur J Nutr. 2023;62(5):2155-64.

[10]. Tuomainen M, Lindström J, Lehtonen M, et al. Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals. Nutr Diabetes. 2018;8(1):35.

[11]. Smits LP, Kootte RS, Levin E, et al. Effect of vegan fecal microbiota transplantation on carnitine- and choline-derived trimethylamine-,-oxide production and vascular inflammation in patients with metabolic syndrome. J Am Heart Assoc. 2018;7(7):e008342.

[12]. Romano KA, Nemet I, Prasad Saha P, et al. Gut microbiota-generated phenylacetylglutamine and heart failure. Circ Heart Fail. 2023;16(1):e009972.

[13]. Di Vincenzo F, Del Gaudio A, Petito V, et al. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2023. doi: 10.1007/s11739-023-03374-w.

[14]. Soderborg TK, Clark SE, Mulligan CE, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun. 2018;9(1):4462.

[15]. Qi X, Yang M, Stenberg J, et al. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol. 2020;26(48):7603-18.

[16]. Robinson MW, Harmon C, O’Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13(3):267-76.

[17]. Alisi A, Carsetti R, Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology. 2011;54(5):1500-2.

[18]. Miura K, Yang L, van Rooijen N, et al. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am J Physiol Gastrointest Liver Physiol. 2012;302(11):G1310-21.

[19]. Tang J, Yan Z, Feng Q, et al. The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol. 2021;12:625472.

[20]. Chen J, Wei Y, He J, et al. Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Sci Rep. 2014;4(1):7259.

[21]. Shen B, Gu T, Shen Z, et al. Escherichia coli promotes endothelial to mesenchymal transformation of liver sinusoidal endothelial cells and exacerbates nonalcoholic fatty liver disease via its flagellin. Cell Mol Gastroenterol Hepatol. 2023;16(6):857-79.

[22]. Grąt M, Wronka KM, Krasnodębski M, et al. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc. 2016;48(5):1687-91.

[23]. Ma C, Han M, Heinrich B, et al. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391):eaan5931.

[24]. Natividad JM, Lamas B, Pham HP, et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat Commun. 2018;9(1):2802.

[25]. Pande A, Sharma S, Khillan V, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial. Hepatol Int. 2023;17(1):249-61.

[26]. Wu W, Kaicen W, Bian X, et al. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microb Biotechnol. 2023;16(10):1924-39.

[27]. Guo W, Cui S, Tang X, et al. Intestinal microbiomics and hepatic metabolomics insights into the potential mechanisms of probiotic , CCFM1253 preventing acute liver injury in mice. J Sci Food Agric. 2023;103(12):5958-69.

[28]. Jiang S, Liu A, Ma W, et al. , CKCC1913 mediated modulation of the gut-liver axis alleviated insulin resistance and liver damage induced by type 2 diabetes. Food Funct. 2023;14(18):8504-20.

[29]. Nguyen HT, Gu M, Werlinger P, et al. , MJM60958 as a potential probiotic alleviated non-alcoholic fatty liver disease in mice fed a high-fat diet by modulating lipid metabolism, inflammation, and gut microbiota. Int J Mol Sci. 2022;23(21):13436.

[30]. Saeedi BJ, Liu KH, Owens JA, et al. Gut-resident lactobacilli activate hepatic Nrf2 and protect against oxidative liver injury. Cell Metab. 2020;31(5):956-968.e5.

[31]. Jiang XW, Li YT, Ye JZ, et al. New strain of , alleviates ethanol-induced liver injury by modulating the gut microbiota and short-chain fatty acid metabolism. World J Gastroenterol. 2020;26(40):6224-40.

[32]. Yu JS, Youn GS, Choi J, et al. , and ,-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease. Clin Transl Med. 2021;11(12):e634.

[33]. Lee NY, Yoon SJ, Han DH, et al. , and , ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020;11(4):882-99.

[34]. Zhang C, Yang M, Ericsson AC. The potential gut microbiota-mediated treatment options for liver cancer. Front Oncol. 2020;10:524205.

[35]. Anand S, Mande SS. Host-microbiome interactions: gut-liver axis and its connection with other organs. NPJ Biofilms Microbiomes. 2022;8(1):89.

[36]. Parlesak A, Schäfer C, Schütz T, et al. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32(5):742-7.

[37]. Dubinkina VB, Tyakht AV, Odintsova VY, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017;5(1):141.

[38]. Chen P, Miyamoto Y, Mazagova M, et al. Microbiota protects mice against acute alcohol-induced liver injury. Alcohol Clin Exp Res. 2015;39(12):2313-23.

[39]. Martino C, Zaramela LS, Gao B, et al. Acetate reprograms gut microbiota during alcohol consumption. Nat Commun. 2022;13(1):4630.

[40]. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9.

[41]. Li S, Tan HY, Wang N, et al. Recent insights into the role of immune cells in alcoholic liver disease. Front Immunol. 2019;10:1328.

[42]. Song K, Coleman RA, Alber C, et al. TH1 cytokine response of CD57+ T-cell subsets in healthy controls and patients with alcoholic liver disease. Alcohol. 2001;24(3):155-67.

[43]. Almeida J, Polvorosa MA, Gonzalez-Quintela A, et al. Altered distribution of peripheral blood maturation-associated B-cell subsets in chronic alcoholism. Alcohol Clin Exp Res. 2015;39(8):1476-84.

[44]. Konopelski P, Ufnal M. Indoles—gut bacteria metabolites of tryptophan with pharmacotherapeutic potential. Curr Drug Metab. 2018;19(10):883-90.

[45]. Li X, Zhang B, Hu Y, et al. New insights into gut-bacteria-derived indole and its derivatives in intestinal and liver diseases. Front Pharmacol. 2021;12:769501.

[46]. Beaumont M, Neyrinck AM, Olivares M, et al. The gut microbiota metabolite indole alleviates liver inflammation in mice. FASEB J. 2018;32(12):fj201800544.

[47]. Ji Y, Gao Y, Chen H, et al. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients. 2019;11(9):2062.

[48]. Krishnan S, Ding Y, Saedi N, et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep. 2018;23(4):1099-111.

[49]. Zheng TX, Pu SL, Tan P, et al. Liver metabolomics reveals the effect of , on alcoholic liver disease. Front Physiol. 2020;11:595382.

[50]. Chung SH, Kim IH, Park HG, et al. Synthesis of conjugated linoleic acid by human-derived bifidobacterium breve LMC 017: utilization as a functional starter culture for milk fermentation. J Agric Food Chem. 2008;56(9):3311-6.

[51]. Dahiya DK, Puniya AK. Isolation, molecular characterization and screening of indigenous lactobacilli for their abilities to produce bioactive conjugated linoleic acid (CLA). J Food Sci Technol. 2017;54(3):792-801.

[52]. Gao S, He Y, Zhang L, et al. Conjugated linoleic acid ameliorates hepatic steatosis by modulating intestinal permeability and gut microbiota in ob/ob mice. Food Nutr Res. 2022;66:8226.

[53]. Marchix J, Catheline D, Duby C, et al. Interactive effects of maternal and weaning high linoleic acid intake on hepatic lipid metabolism, oxylipins profile and hepatic steatosis in offspring. J Nutr Biochem. 2020;75:108241.

[54]. Zhu Y, Dwidar M, Nemet I, et al. Two distinct gut microbial pathways contribute to meta-organismal production of phenylacetylglutamine with links to cardiovascular disease. Cell Host Microbe. 2023;31(1):18-32.e9.

[55]. Nemet I, Saha PP, Gupta N, et al. A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors. Cell. 2020;180(5):862-877.e22.

[56]. Wei W, Wong CC, Jia Z, et al. , uses dietary inulin to suppress NASH via its metabolite pentadecanoic acid. Nat Microbiol. 2023;8(8):1534-48.

[57]. Lv L, Mu D, Du Y, et al. Mechanism of the immunomodulatory effect of the combination of live ,, ,, ,, and , on immunocompromised rats. Front Immunol. 2021;12:694344.

[58]. Yoon SJ, Yu JS, Min BH, et al. ,-derived short-chain fatty acids and indole compounds attenuate nonalcoholic fatty liver disease by modulating gut-liver axis. Front Microbiol. 2023;14:1129904.

[59]. Yeoh BS, Saha P, Golonka RM, et al. Enterohepatic shunt-driven cholemia predisposes to liver cancer. Gastroenterology. 2022;163(6):1658-1671.e16.

[60]. Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun. 2021;12(1):187.

[61]. Yang M, Khoukaz L, Qi X, et al. Diet and gut microbiota interaction-derived metabolites and intrahepatic immune response in NAFLD development and treatment. Biomedicines. 2021;9(12):1893.

[62]. Liu AN, Xu CF, Liu YR, et al. Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023;57(8):872-85.

[63]. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97-101.

[64]. Oleszycka E, O’Brien EC, Freeley M, et al. Bile acids induce IL-1α and drive NLRP3 inflammasome-independent production of IL-1β in murine dendritic cells. Front Immunol. 2023;14:1285357.

[65]. Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761-74.

[66]. Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of Farnesoid X receptor signaling in nonalcoholic fatty liver disease. Mol Nutr Food Res. 2019;63(17):e1900257.

[67]. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-89.

[68]. Jang HR, Lee HY. Mechanisms linking gut microbial metabolites to insulin resistance. World J Diabetes. 2021;12(6):730-44.

[69]. Caricilli AM, Saad MJ. The role of gut microbiota on insulin resistance. Nutrients. 2013;5(3):829-51.

[70]. Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest. 2020;130(3):1453-60.

[71]. Helsley RN, Miyata T, Kadam A, et al. Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. Elife. 2022;11:e76554.

[72]. Addolorato G, Ponziani FR, Dionisi T, et al. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. Liver Int. 2020;40(4):878-88.

[73]. Yang M, Qi X, Li N, et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023;14(1):228.

[74]. Yan J, Nie Y, Liu Y, et al. Yiqi-Bushen-Tiaozhi recipe attenuated high-fat and high-fructose diet induced nonalcoholic steatohepatitis in mice via gut microbiota. Front Cell Infect Microbiol. 2022;12:824597.

[75]. Jia R, Sadiq FA, Liu W, et al. Protective effects of , ASAG 216 on growth performance, antioxidant capacity, gut microbiota and tissues residues of weaned piglets fed deoxynivalenol contaminated diets. Food Chem Toxicol. 2021;148:111962.

[76]. Liu S, Kang W, Mao X, et al. Melatonin mitigates aflatoxin B1-induced liver injury via modulation of gut microbiota/intestinal FXR/liver TLR4 signaling axis in mice. J Pineal Res. 2022;73(2):e12812.

[77]. Zhu W, Xu Y, Liu J, et al. Effects of dietary pork fat cooked using different methods on glucose and lipid metabolism, liver inflammation and gut microbiota in rats. Foods. 2021;10(12):3030.

[78]. Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol. 2019;70(2):249-59.

[79]. Carbajo-Pescador S, Porras D, García-Mediavilla MV, et al. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech. 2019;12(5):dmm039206.

[80]. Gao LL, Ma JM, Fan YN, et al. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol. 2021;183:1379-92.

[81]. Csader S, Chen X, Leung H, et al. Gut ecological networks reveal associations between bacteria, exercise, and clinical profile in non-alcoholic fatty liver disease patients. mSystems. 2023;8(5):e0022423.

[82]. Zhang C, Yang M. Current options and future directions for NAFLD and NASH treatment. Int J Mol Sci. 2021;22(14):7571.

[83]. Shi T, Yu L, Zhuang R, et al. Regulation of mitochondrial function by natural products for the treatment of metabolic associated fatty liver disease. Can J Gastroenterol Hepatol. 2021;2021:5527315.

[84]. Tiller NB, Stringer WW. Exercise-induced increases in “liver function tests” in a healthy adult male: is there a knowledge gap in primary care? J Family Med Prim Care. 2023;12(1):177-80.

[85]. Martinez JE, Kahana DD, Ghuman S, et al. Unhealthy lifestyle and gut dysbiosis: a better understanding of the effects of poor diet and nicotine on the intestinal microbiome. Front Endocrinol (Lausanne). 2021;12:667066.

[86]. Yang M, Liu S, Zhang C. The related metabolic diseases and treatments of obesity. Healthcare (Basel). 2022;10(9):1616.

[87]. Giammarino AM, Qiu H, Bulsara K, et al. Community socioeconomic deprivation predicts nonalcoholic steatohepatitis. Hepatol Commun. 2022;6(3):550-60.

[88]. Askgaard G, Fleming KM, Crooks C, et al. Socioeconomic inequalities in the incidence of alcohol-related liver disease: a nationwide Danish study. Lancet Reg Health Eur. 2021;8:100172.

[89]. Dai S, Wang Z, Yang Y, et al. PM(25) induced weight loss of mice through altering the intestinal microenvironment: mucus barrier, gut microbiota, and metabolic profiling. J Hazard Mater. 2022;431:128653.

[90]. Dong X, Yao S, Deng L, et al. Alterations in the gut microbiota and its metabolic profile of PM(25) exposure-induced thyroid dysfunction rats. Sci Total Environ. 2022;838(Pt 3):156402.

[91]. Ran Z, An Y, Zhou J, et al. Subchronic exposure to concentrated ambient PM25 perturbs gut and lung microbiota as well as metabolic profiles in mice. Environ Pollut. 2021;272:115987.

[92]. Yi W, Ji Y, Gao H, et al. Does the gut microbiome partially mediate the impact of air pollutants exposure on liver function? Evidence based on schizophrenia patients. Environ Pollut. 2021;291:118135.

[93]. Fu L, Qian Y, Shang Z, et al. Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: emerging role of gut microbiota dysbiosis. Front Med (Lausanne). 2022;9:972518.

[94]. Gong S, Feng Y, Zeng Y, et al. Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J Transl Med. 2021;19(1):147.

[95]. Pinato DJ, Li X, Mishra-Kalyani P, et al. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma. JHEP Rep. 2023;5(6):100747.

[96]. Zhang H, Yan A, Liu X, et al. Melatonin ameliorates ochratoxin A induced liver inflammation, oxidative stress and mitophagy in mice involving in intestinal microbiota and restoring the intestinal barrier function. J Hazard Mater. 2021;407:124489.

[97]. Li X, Du Y, Xue C, et al. SIRT2 deficiency aggravates diet-induced nonalcoholic fatty liver disease through modulating gut microbiota and metabolites. Int J Mol Sci. 2023;24(10):8970.

[98]. Hsu CF, Huang CC, Liu TT, et al. Deletion of intestinal SIRT1 exacerbated muscle wasting in cirrhotic mice by decreasing the intestinal concentration of short-chain fatty acids and inflammation. J Pharmacol Sci. 2021;147(4):376-85.

[99]. Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306.

[100]. Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):1055-65.

[101]. Lei Y, Tang L, Chen Q, et al. Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism. Nat Commun. 2022;13(1):6862.

[102]. He K, Guo LL, Tang H, et al. A freshwater fish-based diet alleviates liver steatosis by modulating gut microbiota and metabolites: a clinical randomized controlled trial in Chinese participants with nonalcoholic fatty liver disease. Am J Gastroenterol. 2022;117(10):1621-31.

[103]. Mohamad Nor MH, Ayob N, Mokhtar NM, et al. The effect of probiotics (MCP(®) BCMC(®) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients. 2021;13(9):3192.

[104]. Tenorio-Jiménez C, Martínez-Ramírez MJ, Tercero-Lozano M, et al. Evaluation of the effect of , V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR). BMC Complement Altern Med. 2018;18(1):306.

[105]. Escouto GS, Port GZ, Tovo CV, et al. Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial. J Nutr. 2023;153(7):1984-93.

[106]. Manzhalii E, Moyseyenko V, Kondratiuk V, et al. Effect of a specific , Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment. World J Hepatol. 2022;14(3):634-46.

[107]. Scorletti E, Afolabi PR, Miles EA, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020;158(6):1597-1610.e7.

[108]. Patel VC, Lee S, McPhail MJW, et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. J Hepatol. 2022;76(2):332-42.

[109]. Loomba R, Ling L, Dinh DM, et al. The commensal microbe , as a marker for response to an FGF19 analog in NASH. Hepatology. 2021;73(1):126-43.

[110]. Rodriguez J, Neyrinck AM, Van Kerckhoven M, et al. Physical activity enhances the improvement of body mass index and metabolism by inulin: a multicenter randomized placebo-controlled trial performed in obese individuals. BMC Med. 2022;20(1):110.

[111]. Depommier C, Everard A, Druart C, et al. Supplementation with , in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-103.

[112]. Ng SC, Xu Z, Mak JWY, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial. Gut. 2022;71(4):716-23.,

引用本文

Yang, Ming; Massad, Katina; Kimchi, Eric T.; Staveley-O'Carroll, Kevin F.; Li, Guangfu. Gut microbiota and metabolite interface-mediated hepatic inflammation [J]. Immunometabolism. 2024; 6; (1). 1 - 12.

文献评论

相关学者

相关机构